Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 7:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 621 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Subutex Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of ALKS 5461 on QT Intervals in Healthy Volunteers

NCT02479308
View directory record Official record
Conditions
Healthy
Interventions
Moxifloxacin, ALKS 5461, Placebo
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
129 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 23, 2015 · Synced Oct 27, 2026, 7:29 AM EDT
Recruiting Phase 3 Interventional

Standard Versus High Dose ED-Initiated Buprenorphine Induction

NCT06494904
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Buprenorphine
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
5
States / cities
Oakland, California • San Leandro, California • Portland, Maine + 2 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 27, 2026, 7:29 AM EDT
Completed Phase 3 Interventional Results available

Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Chronic Low Back Pain

NCT00490919
View directory record Official record
Conditions
Low Back Pain
Interventions
Buprenorphine transdermal system, Placebo
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years and older
Enrollment
539 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
86
States / cities
Anniston, Alabama • Mobile, Alabama • Chandler, Arizona + 71 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2012 · Synced Oct 27, 2026, 7:29 AM EDT
Completed Phase 1 Interventional Results available

A Study to Assess the Effect of a Single Dose of ASP8062 on the Multiple Dose Safety, Tolerability and Pharmacokinetics of Buprenorphine/Naloxone in Participants With Opioid Use Disorder

NCT04447287
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
ASP8062, Placebo ASP8062, buprenorphine/naloxone
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Oct 27, 2026, 7:29 AM EDT
Completed Not applicable Interventional Results available

Virtual Pain Care Management (COVID-19)

NCT04539821
View directory record Official record
Conditions
Chronic Pain
Interventions
VCPM
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Aurora, Colorado • West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 14, 2024 · Synced Oct 27, 2026, 7:29 AM EDT
Completed Phase 1 Interventional Results available

An Adaptive Walking Intervention to Manage Chronic Pain in Veterans With Opioid Use Disorder Engaged in Opioid Agonist Treatment

NCT05051644
View directory record Official record
Conditions
Opioid Use Disorder, Chronic Pain
Interventions
Steps 2 Change (S2C), Control
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 27, 2026, 7:29 AM EDT
Completed Not applicable Interventional

Pilot Trial of Opioid Taper Support

NCT01883882
View directory record Official record
Conditions
Chronic Non-cancer Pain
Interventions
opioid taper support
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 80 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 24, 2016 · Synced Oct 27, 2026, 7:29 AM EDT
Completed Phase 3 Interventional

Re-Treatment Study of Probuphine in Opioid Addiction

NCT01262261
View directory record Official record
Conditions
Opioid Dependency
Interventions
Probuphine (buprenorphine implant)
Drug
Lead sponsor
Titan Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
18
States / cities
Los Angeles, California • National City, California • Oceanside, California + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2018 · Synced Oct 27, 2026, 7:29 AM EDT
Completed Phase 3 Interventional

Transdermal Patch for BupRenorphine Induction DurinG PrEgnancy (Patch BRIDGE)

NCT05790252
View directory record Official record
Conditions
Opioid Use Disorder, Pregnancy Related, Pregnancy, High Risk, Pregnancy Complications, Buprenorphine Withdrawal
Interventions
Buprenorphine Transdermal Matrix Patch, Sham patch
Drug · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 110 Years · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 27, 2026, 7:29 AM EDT
Completed No phase listed Observational

SUBLOCADE Long-term Outcomes

NCT05860959
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Not listed
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years and older
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
35
States / cities
Costa Mesa, California • Escondido, California • Westport, Connecticut + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2025 · Synced Oct 27, 2026, 7:29 AM EDT
Recruiting Not applicable Interventional

Adaptive Interventions for Emergency Department Patients With Opioid Use Disorder

NCT06827288
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
SUN, SUN + Telebridge, ED-ITT, ED-ITT + BHS
Behavioral
Lead sponsor
RAND
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Colton, California
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 27, 2026, 7:29 AM EDT
Completed Phase 3 Interventional

Linking Hospitalized Injection Drug Users to Buprenorphine

NCT00987961
View directory record Official record
Conditions
Opiate Dependence
Interventions
Linkage
Behavioral
Lead sponsor
Butler Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 11, 2015 · Synced Oct 27, 2026, 7:29 AM EDT
Active, not recruiting Not applicable Interventional

Pain Care at Home to Amplify Function (Pain CHAMP)

NCT05333341
View directory record Official record
Conditions
Opioid Use Disorder, Opioid Misuse, Chronic Pain
Interventions
TCM, TCM plus COPES
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
259 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
3
States / cities
Little Rock, Arkansas • Aurora, Colorado • West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 30, 2026 · Synced Oct 27, 2026, 7:29 AM EDT
Recruiting No phase listed Observational

Impact of Federal and State Medications for Opioid Use Disorder (MOUD) Policy Changes During the Pandemic

NCT07232641
View directory record Official record
Conditions
Substance Use Disorders, Alcohol Use Disorder, Opioid Use Disorder
Interventions
Not listed
Lead sponsor
Boston University
Other
Eligibility
18 Years and older
Enrollment
185,810 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 27, 2026, 7:29 AM EDT
Terminated No phase listed Observational

The Effects of Opioid Taper on Opioid-Induced Hyperalgesia

NCT03063905
View directory record Official record
Conditions
Buprenorphine, Pain
Interventions
Buprenorphine
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years to 50 Years
Enrollment
15 participants
Timeline
2017 – 2018
U.S. locations
2
States / cities
Rockville, Maryland • Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 21, 2018 · Synced Oct 27, 2026, 7:29 AM EDT
Not yet recruiting Not applicable Interventional

Measurement-Based Care to Support Buprenorphine-Naloxone Treatment in Outpatient Addiction Clinics

NCT07839182
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Bup-MBC
Behavioral
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 27, 2026, 7:29 AM EDT
Completed Phase 2 Interventional Results available

Multiple Dose Pharmacokinetics Depot Buprenorphine in Opioid-Dependent Subjects

NCT01738503
View directory record Official record
Conditions
Opioid Related Disorder
Interventions
RBP-6000, Subutex
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 23, 2018 · Synced Oct 27, 2026, 7:29 AM EDT
Recruiting Phase 2 Interventional

Low-dose Buprenorphine as a Modulator of Social Motivation in Schizophrenia

NCT05778591
View directory record Official record
Conditions
Schizophrenia
Interventions
Placebo, Buprenorphine 0.15 MG [Belbuca]
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 27, 2026, 7:29 AM EDT
Completed Phase 1 Interventional

Pharmacokinetics, Safety, and Tolerability of Depot Buprenorphine at Three Different Molecular Weights in Treatment-Seeking Subjects With Opioid Use Disorder

NCT02559973
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
RBP-6000, SUBOXONE Sublingual Film
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 31, 2017 · Synced Oct 27, 2026, 7:29 AM EDT
Completed Phase 3 Interventional Results available

Dane County Drug Court Study for Addicted Offenders

NCT01843751
View directory record Official record
Conditions
Opioid Dependence
Interventions
buprenorphine/naloxone
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
16 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 7, 2023 · Synced Oct 27, 2026, 7:29 AM EDT
Withdrawn Phase 2 Interventional

Olanzapine in OUD Patients

NCT05179772
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Olanzapine
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 1, 2023 · Synced Oct 27, 2026, 7:29 AM EDT
Completed Phase 2 Interventional

Buprenorphine Pharmacology Related to Addiction Treatment - 21

NCT00000239
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Buprenorphine
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
0 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Aug 17, 2005 · Synced Oct 27, 2026, 7:29 AM EDT
Completed Not applicable Interventional Results available

Psychosocial Pain Management to Improve Opioid Use Disorder Treatment Outcomes

NCT04433975
View directory record Official record
Conditions
Opioid-use Disorder, Medication Assisted Treatment, Chronic Pain
Interventions
Psychosocial Pain Management (PPMI), Enhanced Usual Care (EUC)
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
2
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 9, 2025 · Synced Oct 27, 2026, 7:29 AM EDT
Completed Not applicable Interventional Results available

Surmounting Withdrawal to Initiate Fast Treatment With Naltrexone

NCT04762537
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Standard Induction Procedure (SP), Rapid Induction Procedure (RP)
Other
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years and older
Enrollment
415 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
6
States / cities
Orlando, Florida • Rockville, Maryland • Cape Girardeau, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2023 · Synced Oct 27, 2026, 7:29 AM EDT